Efficacy and safety of repository corticotropin injection for refractory cutaneous dermatomyositis: a prospective, open-label study
An erratum to this article was published (Rheumatology (Oxford), 1 Mar 2025 ↗)
Authors' conclusion
RCI treatment resulted in statistically significant and clinically meaningful improvement in cutaneous DM activity and quality of life.
Study context
- Population
- Dermatomyositis (DM) patients with moderate-to-severe cutaneous activity (CDASI-A >14) despite prior treatment with ≥2 systemic agents15 completed 6 months
- Participants
- 19 patients
- Outcome
- Significant decreases in CDASI-A and PGA scores
- Follow-up
- 6 months
Main finding
As reported in the abstract
Co-primary: CDASI-A and PGA scores
Median baseline CDASI-A score
19.0
Median CDASI-A score at 6 months (statistically significant improvement)
10.0
Median baseline Physician's Global Assessment (PGA) activity score
2.5/10
Median PGA score at 6 months (statistically significant improvement)
0.8/10
Observational data: associations, not effects.
Further findings
Patient global skin score (PtGSS) · 6 months
- Baseline median PtGSS
- 3.0/10
- Median PtGSS at 6 months (statistically significant improvement)
- 7.0
Dermatology life quality index (DLQI) · 6 months
- Baseline median DLQI score
- 7.0/10
- Median DLQI score at 6 months (statistically significant improvement)
- 2.0
Safety
- Adverse effects were mild
Original publication
Efficacy and safety of repository corticotropin injection for refractory cutaneous dermatomyositis: a prospective, open-label study. Rheumatology (Oxford). Published 6 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →